The Challenges of Interstitial Cystitis: Current Status and Future Prospects

Area of Science:

• Urology
• Pain Management
• Biomarker Discovery

Background:

• Interstitial cystitis/bladder pain syndrome (IC/BPS) presents with bladder pain and urinary symptoms.
• Current treatments target proposed etiologies like urothelial dysfunction, inflammation, or neuropathic pain.
• Effective treatment is hindered by the inability to distinguish between off-target therapies and sub-therapeutic interventions.

Purpose of the Study:

• To highlight the critical need for biomarkers in IC/BPS treatment.
• To propose a future direction for personalized medicine in IC/BPS.

Main Methods:

• Review of current understanding of IC/BPS etiologies and treatment strategies.
• Analysis of the challenges in differentiating treatment failures.
• Conceptual proposal for biomarker-guided therapy selection and monitoring.

Main Results:

• IC/BPS has multiple proposed etiologies, complicating treatment selection.
• Treatment failure can result from targeting the wrong cause or using insufficient therapy.
• The lack of specific biomarkers prevents precise patient stratification and treatment monitoring.

Conclusions:

• Identifying specific urine or serum biomarkers for each IC/BPS etiology is crucial.
• Biomarkers would enable patient selection for targeted treatments.
• Biomarkers would allow monitoring of treatment efficacy on the intended biological target, advancing IC/BPS management.